Importantly, these findings have immediate clinical implications, as testing for NTRK gene fusions in spontaneous MSI-H and BRAF wild-type CRC cases could identify patients who may benefit from NTRK-directed therapies. The gene discussed is BRAF; the disease is colorectal carcinoma.